We're a seed-stage company developing a universal cure for the flu. Our therapy is based on a small protein product with the capacity to interfere with the basic biology utilized by every strain of the influenza virus family. The product is structurally stable and adaptable to many different formulations. And because it blocks multiple aspects of virus replication, resistance to this antiviral is not possible. Our preclinical models show a complete reduction of both morbidity and mortality for every Influenza A Virus strain and Influenza B Virus, as well. No existing vaccine or therapy can achieve these results. This protein was discovered by Archean’s Scientific Co-founder, Dr. Ben tenOever, and we’ve in-licensed the molecule to refine delivery and formulation options.